Apologies for X posting as I have posted this to the EBH list.
Dear Colleague,
Warm autumn greetings and a very good afternoon from sunny Suffolk in the
East
of England.
Today’s NEJM carries two very interesting perspectives from eminent
colleagues across the Atlantic.
Dangerous Deception — Hiding the Evidence of Adverse Drug Effects.
Observational Studies of Drug Safety — Aprotinin and the Absence of
Transparency
In the era when the commissioners and those who fund health care are
pressurised to rapidly adopt and fund newer drugs these two perspectives put
this issue in perspective. This is much more relevant in publicly funded
health systems where the resources have to be deployed judiciously to derive
maximum health gain for our population for every single unit of currency we
spend.
Thanks to NEJM, which has provided both these perspectives, free access and
they are available @
http://content.nejm.org/cgi/reprint/355/21/2169.pdf
http://content.nejm.org/cgi/reprint/355/21/2171.pdf
I thought this might be of interest to some members on our list.
Warm regards & very best wishes,
Badri
Dr P Badrinath MD M.Phil MPH FFPH PhD (Cantab)
Consultant in Public Health Medicine & Affiliated Clinical Lecturer
Suffolk PCT & University of Cambridge
Thingoe House, Bury St Edmunds, Suffolk, UK
http://myprofile.cos.com/badrishanthi
|